KRAS and neoplasm: The double inhibition of the mutant driver oncogene, on tissue level with PPARγ agonists, reprogramming inflammation, immune response, inducing tumor cell differentiation and on tumor cell level with KRAS inhibitors, might attenuate the proliferative stimulus, and could be in future a suitable preventive and therapeutic approach (99, 134).